Hula Therapeutics is a clinical-stage precision immunotherapy company developing treatments for solid cancers. The company combines immunopeptidomics with novel protein engineering to target previously untapped, tumor-specific intracellular antigens. This approach is designed to be compatible with various immunotherapies and effectively deliver therapeutics across a broad distribution of HLA allotypes.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HBFounders
Product
Problem
Childhood cancers often require aggressive treatments that can result in significant short-term and long-term side effects due to the lack of therapies specifically designed for pediatric tumors. The unique genetic and biological characteristics of pediatric cancers are often not adequately addressed by treatments developed for adult cancers.
Solution
Hula Therapeutics is developing targeted therapies designed specifically for childhood cancers, leveraging precision medicine to improve treatment outcomes and reduce adverse effects. Their approach focuses on identifying and targeting the unique genetic profiles of pediatric tumors, allowing for more effective and less toxic treatments. By tailoring therapies to the specific characteristics of each child's cancer, Hula Therapeutics aims to increase the chances of successful treatment while minimizing the long-term health consequences for young patients. This precision approach seeks to address the unmet need for cancer treatments that are both effective and gentle for children.
Target Audience
The primary target audience includes pediatric oncology patients, their families, and the healthcare professionals who treat childhood cancers.
Features
- Focus on targeted therapies for pediatric cancers.
- Precision medicine approach based on the unique genetic profiles of pediatric tumors.
- Development of treatments designed to minimize side effects in children.